This is a profile image of Edd Fleming

Edd Fleming

Senior Partner, Bay Area

Leverages medical training to help pharmaceutical firms plan and execute growth strategies, improve R&D productivity, and optimize product portfolios


Edd is one of several physicians at McKinsey, where he focuses on supporting clients across the healthcare sector. He leads McKinsey’s Life Sciences R&D Practice and hosts its Chief Medical Officers Forum, a knowledge sharing event that explores critical medical topics such as product safety and data privacy and sharing.

He works extensively across the healthcare sector to improve organizations’ growth, commercialization, distribution, care delivery, and R&D capabilities and processes. He brings pharmaceutical clients deep expertise in biopharmaceuticals and diagnostics, as well as a broad range of client support. Since joining McKinsey, Edd contributed to improving the R&D, medical-affairs, and drug-safety functions at drug and device manufacturers, and also assisted in refining operations and care delivery at academic medical centers.

Edd has worked closely with pharmaceutical companies over the past decade as healthcare reform and regulatory changes have reconfigured the industry landscape. His recent client contributions for biopharmaceutical clients include helping design the product development strategy for immunologic therapies; conducting strategic assessments of the cardiovascular and oncology therapeutic areas; spearheading an R&D portfolio prioritization of oncology, immunology, and infectious disease therapies for a third company; and redesigning the global safety and compliance activities of another company.

He also has significant experience in the area of personalized medicine, helping companies assess proposed diagnostic products. At one firm, he developed the launch and life-cycle strategy for an innovative biologic and companion diagnostic in the respiratory area and assisted in the creation of multiple pricing strategies for personalized diagnostics at a different company. He recently supported a large academic medical center as it developed a business plan and funding strategy for a personalized disease-management team in hematologic malignancies.

Edd is board-certified in pulmonary, critical care, and internal medicine.

Published work

CROs and biotech companies: Fine-tuning the partnership,” McKinsey & Company, June 2022

Innovation sourcing in biopharma: Four practices to maximize success,” McKinsey & Company, May 2022

Transforming biopharma R&D at scale,” McKinsey & Company, May 2022

A new portfolio model for biotech,” McKinsey & Company, January 2021

Precision medicine: Opening the aperture,” McKinsey & Company, February 2019

Digital R&D: The Next Frontier for Biopharmaceuticals,” McKinsey & Company, October 2018

R&D in the ‘age of agile’,” McKinsey & Company, October 2018

Real-world evidence: Driving a new drug development paradigm in oncology,” McKinsey & Company, July 2018

Pharma medical affairs 2020 and beyond,” (PDF–1.74 MB), Pharma R&D compendium, 2010

Well done is half begun: Success factors in companion diagnostics,” (PDF—7.46 MB), McKinsey Personalized Medicine compendium, 2013

Invention reinvented: McKinsey perspectives on pharmaceutical R&D,” (PDF—1.74 MB), Pharma R&D compendium, 2010


Vanderbilt Medical School

Harvard University
BA, chemistry